NCM
PTLA

Nelson Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Nelson Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$39K – 306
2017
Q1 		$39K Buy
+1,000
New +$31.8K 0.01% 139

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Nelson Capital Management's PTLA Position: Q2 2017 in Review

Nelson Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017, closing a stake of 1,000 shares — an estimated $39K sold.

Nelson Capital Management first reported a position in PTLA in Q1 2017 and held it in 1 quarter. The position peaked at $39K in Q1 2017. 206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

  • Nelson Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Nelson Capital Management sold 1,000 Portola Pharmaceuticals, Inc. shares in Q2 2017, an estimated $39K.
  • Nelson Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Nelson Capital Management's Portola Pharmaceuticals, Inc. position peaked at $39K in Q1 2017.
  • 206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Nelson Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.